- Home
- CASI
as 05-30-2025 4:00pm EST
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
| Founded: | 1991 | Country: | China |
| Employees: | N/A | City: | N/A |
| Market Cap: | 29.7M | IPO Year: | 1996 |
| Target Price: | $4.00 | AVG Volume (30 days): | 7.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.55 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.64 - $7.67 | Next Earning Date: | 05-16-2025 |
| Revenue: | $31,368,000 | Revenue Growth: | 8.39% |
| Revenue Growth (this year): | -32.8% | Revenue Growth (next year): | N/A |
Latest CASI Pharmaceuticals Inc. News
CASI Breaking Stock News: Dive into CASI Ticker-Specific Updates for Smart Investing
ACCESS Newswire
12 days ago
CASI Pharmaceuticals Provides Business and Clinical Update
ACCESS Newswire
16 days ago
CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results
MT Newswires
19 days ago
CASI to Divest Two Subsidiaries in China
ACCESS Newswire
20 days ago
CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China
ACCESS Newswire
25 days ago
CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement
ACCESS Newswire
2 months ago
CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company
Simply Wall St.
2 months ago
CASI Pharmaceuticals Full Year 2024 Earnings: US$2.56 loss per share (vs US$2.02 loss in FY 2023)
ACCESS Newswire
2 months ago
CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results
Compare CASI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CASI CASI Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.